Article
17 Jan 2024
Invalidity Of A Patent Claiming Antibodies Characterized By Their Function In View Of Amgen
AUTHORS CONTENT
Article
24 Apr 2023
A Broad Outline Of A Genus's Perimeter Is Insufficient For Written Description Of The Members Of The Genus
Article
18 Apr 2023
Anticipation Under The Public Use Bar
Article
13 Mar 2023
USPTO Announces All Patent Term Extension Requests To Be Filed Electronically
Article
28 Feb 2023
Claims Directed To Detecting Natural Phenomena Using Conventional Techniques Are Patent Ineligible
Article
01 Nov 2022
A Class Of 957 Predicted Salts Is Insufficient To Meet The ‘At Once Envisage' Standard
Article
25 Oct 2022
USPTO Extends Cancer Immunotherapy Pilot Program
Article
06 Oct 2022
Failure To Identify The Invention And To Explain How You Do It May Lead To Invalidity Under Section 101
Article
07 Sep 2022
Product-by-Process Claim: The Focus Is On The Product And Not The Process Of Making It
Article
30 Mar 2022
Patent Invalidation Under Section102(b)'s On-Sale Bar Based On A Letter Including Commercial Terms Sent Before The Critical Date
Article
20 Oct 2021
Another Example Of Invalid Claims For Lack Of Written Description And Enablement
Article
24 Aug 2021
Claims To A Spread-Spectrum Method For Sending Data Over A Communications Channel Are Patent Ineligible Under Section 101
Article
07 Jul 2021
A Digital Camera (A Mechanical/Electronic Device) Is Patent Ineligible
Article
11 May 2021
Reliance On A Single Non-Enabling Reference To Establish Obviousness
Article
07 Apr 2021
Claims Directed To Computerized Statistical Methods For Determining Haplotype Phase Are Patent Ineligible
Article
10 Mar 2021
Invalidation Of Chemical Compound Claims
Article
03 Feb 2021
USPTO: Proposed Changes To Terminal Disclaimer Practice In Joint Research Agreement Situations
Article
06 Jan 2021
Small Entity Government Use License Exception: Amendment Of The Rules Of Practice In Patent Cases
Article
20 Oct 2020
Must A "Human Antibody" Be Entirely Human? Or May It Also Be "Partially Human?"
Article
15 Oct 2020
Inadequate Translation Of A Non-English Application Leads To US Patent Invalidation